Living Cell Technologies Limited (LCT) is a global pioneer in the field of cell encapsulation and implantation for human therapeutics.
DIABECELL is currently in late-stage clinical trials, having completed a successful Phase I/IIa clinical trial in Russia and following the positive results from the interim analysis of the Phase IIa safety and efficacy trial. Safety and preliminary efficacy data generated to date show promise that DIABECELL will change the paradigm for treating diabetes when it becomes the world's first approved porcine cell implant.
On 1 November 2011 LCT and Otsuka Pharmaceutical Factory, Inc. created a new company Diatranz Otsuka Limited (DOL) with cash of $A25,000,000 to accelerate the development and commercialisation of DIABECELL.
Using breakthrough proprietary micro-encapsulation technology, IMMUPEL™, which enables implantation of cell-based therapeutics without immunosuppression, LCT is developing NTCELL®, a choroid plexus cell product which is currently in Phase I clinical trials in New Zealand for Parkinson's disease. NTCELL has also shown a powerful ability to regenerate tissue and restore function in animal models of Parkinson’s disease, stroke, Huntington's disease, hearing loss and other non-neurological conditions, such as wound healing.